| ORIGINAL RESEARCH ARTICLE |
|
| Year : 2017 | Volume
: 20
| Issue : 2 | Page : 91-95 |
|
|
Clinical evaluation of mineral trioxide aggregate and biodentine as direct pulp capping agents in carious teeth
Swaroop Hegde, B Sowmya, Sylvia Mathew, Shilpa H Bhandi, Shruthi Nagaraja, K Dinesh
Department of Conservative Dentistry and Endodontics, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka, India
Correspondence Address:
B Sowmya
Department of Conservative Dentistry and Endodontics, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, Bengaluru, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0972-0707.212243
|
|
|
Background: Root canal treatment has been a routine treatment option for carious exposure of the dental pulp. In the context of minimally invasive dentistry, direct pulp capping (DPC) procedure with a reliable biomaterial may be considered as an alternative provided the pulp status is favorable. Mineral trioxide aggregate (MTA), a bioactive cement with excellent sealing ability and biocompatibility is capable of regenerating relatively damaged pulp and formation of dentin bridge when used as DPC agent. Biodentine is comparatively a new biomaterial claimed to possess properties similar to MTA and is currently explored for vital pulp therapy procedures.
Aim: The aim of the present study was to evaluate the clinical response of pulp-dentin complex after DPC with MTA and biodentine in carious teeth.
Subjects and Methods: Twenty-four permanent molars with carious exposure having no signs and symptoms of irreversible pulpitis were selected and assigned to one of the two groups, Group I - MTA and Group II - biodentine. Patients were recalled at 3 weeks, 3 months, and 6 months for clinical and radiographic evaluation. Fisher's exact test was used along with Chi-square test for statistical analysis.
Results: Over a period of 6 months, MTA and biodentine showed 91.7% and 83.3% success rate, respectively, based on the subjective symptoms, pulp sensibility tests, and radiographic appearance.
Conclusion: MTA and biodentine may be used as DPC agents when the pulpal diagnosis is not more than reversible pulpitis. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
